ArticleeLife2020
Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections.
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 59 citations in OpenAlex.
- Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistantmSphere · 2026Article
- Combinatorial Antimicrobial Effects of Imidazolium-Based Ionic Liquids and Antifungals on Model Fungal Organisms.Biomolecules · 2025Article
- Fast detection of synergy and antagonism in antifungal combinations used against Candida albicans clinical isolates.Scientific reports · 2025Article
- Non-antifungal medications administered during fungal infections drive drug tolerance and resistance inJournal of medical microbiology · 2025Article
- Landscape of essential growth and fluconazole-resistance genes in the human fungal pathogen Cryptococcus neoformans.PLoS biology · 2025Article
- Synergistic Antifungal Efficacy of Eugenol-Loaded Nanocapsules Combined With Itraconazole Against Trichophyton mentagrophytes.Veterinary medicine and science · 2025Article
- Aloin remodels the cell wall of Candida albicans to reduce its hyphal virulence against oral candidiasis.Applied microbiology and biotechnology · 2025Article
- Review
- Characterization of a New Hsp110 Inhibitor as a Potential Antifungal.Journal of fungi (Basel, Switzerland) · 2024Article
- Review
- In vitro analysis of postbiotic antimicrobial activity against Candida Species in a minimal synthetic model simulating the gut mycobiota in obesity.Scientific reports · 2024Article
- Synergistic activity of gold nanoparticles with amphotericin B on persister cells of Candida tropicalis biofilms.Journal of nanobiotechnology · 2024Article
- Garlic-Derived Quorum Sensing Inhibitors: A Novel Strategy Against Fungal Resistance.Drug design, development and therapy · 2024Review
- Article
- Article
- Article
- Azole potentiation in Candida species.PLoS pathogens · 2023Article
- Phenotypic Array for Identification and Screening of Antifungals againstJournal of fungi (Basel, Switzerland) · 2023Article
- Hydrocinnamic Acid and Perillyl Alcohol Potentiate the Action of Antibiotics againstAntibiotics (Basel, Switzerland) · 2023Article
- Searching for new antifungals for the treatment of cryptococcosis.Revista da Sociedade Brasileira de Medicina Tropical · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Invasive fungal infections cause 1.6 million deaths annually, primarily in immunocompromised individuals. Mortality rates are as high as 90% due to limited treatments. The azole class antifungal, fluconazole, is widely available and has multi-species activity but only inhibits growth instead of killing fungal cells, necessitating long treatments. To improve treatment, we used our novel high-throughput method, the overlap
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.